Bavarian Nordic AS
BV3
Company Profile
Business description
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
Contact
Philip Heymans Alle 3
Hellerup2900
DNKT: +45 33268383
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,861
Stocks News & Analysis
stocks
Chart of the Week: BHP’s valuation hits historic levels
BHP and peers are trading as if the copper boom is here to stay.
stocks
3 cheap wide moat growth stocks
4 and 5 star companies that can protect and grow their earnings.
stocks
ASX biotech expands diagnostics portfolio after FDA approval
FDA nod adds another growth driver for ASX share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,883.50 | 9.00 | 0.10% |
| CAC 40 | 8,140.59 | 50.31 | 0.62% |
| DAX 40 | 25,537.75 | 135.47 | 0.53% |
| Dow JONES (US) | 51,461.90 | 631.21 | -1.21% |
| FTSE 100 | 10,688.47 | 30.34 | 0.28% |
| HKSE | 24,415.22 | 298.56 | -1.21% |
| NASDAQ | 25,978.43 | 3.14 | -0.01% |
| Nikkei 225 | 64,028.26 | 105.26 | 0.16% |
| NZX 50 Index | 13,684.65 | 61.93 | 0.45% |
| S&P 500 | 7,551.81 | 33.92 | -0.45% |
| S&P/ASX 200 | 8,705.90 | 9.40 | 0.11% |
| SSE Composite Index | 3,875.00 | 16.60 | -0.43% |